Articles

RSS

Research Triangle Park, NC - Patheon, a global provider of drug development and manufacturing services to the international pharmaceutical industry announced recently that it has named William E. Weiser, Ph.D. as group director, Pharmaceutical Development Services (PDS), Analytical Development at the company's Kit Creek laboratory located in Research Triangle Park, N.C. At the same time, the company has named Anthony Qu, Ph.D. as group director of its PDS operation in Cincinnati, Ohio.

"We are so pleased that we have been able to add these two individuals to our organization," said Dr. Colin Minchom, Patheon's Vice President PDS North America. "I am confident that our customers and employees will benefit from their broad expertise as leaders and as scientists in research and development."

Dr. Weiser has over 20 years experience in the pharmaceutical industry. Most recently he served as General Manager for Liquidia Pharmaceuticals with responsibility for establishing Pharmaceutical Development operations for their nanoparticle therapeutics as well as formulation and analytical development capabilities. He was Vice President of Analytical Chemistry at Cardinal Health/Magellan Laboratories, Inc., where he significantly contributed to the substantial growth of their contract pharmaceutical analytical services. He also held positions of increasing leadership in Pharmaceutical Development at Burroughs Wellcome Co. He earned a Ph.D. from Purdue University and a B.S. in Chemistry from the College of William and Mary.

Dr. Qu, with almost 20 years experience in the pharmaceutical industry, is returning to Patheon from his most recent position as Vice President of Product Development at Apotex Inc. His previous Patheon experience included responsibilities as Senior Director, of PDS Global Analytical Operations and Director/Manager, PDS Analytical Development in Mississauga, Ontario, Canada. He has also held positions in research and development and regulatory affairs at Biovail Corporation and Taro Pharmaceuticals. He holds a Ph.D. from the University of Toronto as well as Masters in Science and Bachelors in Science degrees from Western China University of Medical Sciences.

About Patheon
Patheon Inc. is a leading global provider of contract development and manufacturing services to the global pharmaceutical industry. Patheon prides itself in providing the highest quality products and services to more than 300 of the world's leading pharmaceutical and biotechnology companies. Patheon's services range from preclinical development through commercial manufacturing of a full array of dosage forms including parenteral, solid, semi-solid and liquid forms. Patheon uses many innovative technologies including single-use disposables, liquid-filled hard capsules and a variety of modified release technologies. Patheon's comprehensive range of fully integrated Pharmaceutical Development Services includes pre-formulation, formulation, analytical development, clinical manufacturing, scale-up and commercialization. Patheon can take customers direct to clinic with global clinical packaging and distribution services and Patheon's Quick to Clinic™ programs can accelerate early phase development project to clinical trials while minimizing the consumption of valuable API. Patheon's integrated development and manufacturing network of ten facilities, and six development centers across North America and Europe, strives to ensure that customer products can be launched with confidence anywhere in the world.

Patheon's integrated development and manufacturing network of 11 facilities and 8 development centers, across North America and Europe, strives to ensure that customer products can be launched timely and confidently anywhere in the world.

SOURCE: Patheon Inc.